Nivolumab + Relatlimab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urologic Neoplasms
Conditions
Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, Urinary Bladder Diseases, Male Urogenital Diseases, Urinary Bladder Neoplasm, Antineoplastics Toxicity
Trial Timeline
Feb 19, 2024 → Aug 1, 2028
NCT ID
NCT06237920About Nivolumab + Relatlimab
Nivolumab + Relatlimab is a phase 2 stage product being developed by Bristol Myers Squibb for Urologic Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06237920. Target conditions include Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07459543 | Approved | Recruiting |
| NCT06237920 | Phase 2 | Recruiting |
| NCT04658147 | Phase 1 | Active |
| NCT04567615 | Phase 2 | Completed |
| NCT04552223 | Phase 2 | Completed |
| NCT03623854 | Phase 2 | Completed |
| NCT03610711 | Phase 1/2 | Active |
| NCT03642067 | Phase 2 | Completed |
Competing Products
16 competing products in Urologic Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| Mirabegron + Solifenacin succinate + Placebo | Astellas Pharma | Phase 2 | 52 |
| Mirabegron + Solifenacin succinate | Astellas Pharma | Phase 3 | 77 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| ALIMTA + gemcitabine | Eli Lilly | Phase 2 | 52 |
| BBI503 | Sumitomo Pharma | Phase 2 | 52 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 52 |
| Carboplatin/Paclitaxel + Pembrolizumab | Merck | Phase 2 | 52 |
| zoledronic acid | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 51 |
| CBT101 + Placebo | Brain Biotech | Phase 1 | 25 |
| OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin | Achieve Life Sciences | Phase 2 | 44 |
| S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel | Achieve Life Sciences | Phase 2 | 44 |
| Stem Cell | Brain Biotech | Phase 1 | 25 |